Product image of Mifomet (Metformin Hydrochloride, Sitagliptin) supplied by GNH India

Mifomet

Active Ingredient:
Metformin Hydrochloride, Sitagliptin
Origin:
EU

Mifomet (Metformin Hydrochloride, Sitagliptin)

Metformin Hydrochloride and Sitagliptin, the active ingredients in Mifomet, are a biguanide and a DPP‑4 inhibitor presented as an oral tablet for oral use. They treat type 2 diabetes mellitus in adults by improving insulin sensitivity and enhancing glucose‑dependent insulin secretion, targeting both hepatic glucose production and incretin pathways for complementary glycaemic control.

GNH India supplies Mifomet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Bausch Health Ireland Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mifomet is indicated for the management of type 2 diabetes mellitus, a chronic metabolic disorder requiring pharmacologic glycaemic control.

  • Type 2 diabetes mellitus: improves overall blood glucose control when diet, exercise, and monotherapy are insufficient.
  • Adjunct therapy: used together with other antidiabetic agents such as insulin or sulfonylureas to achieve target HbA1c levels.
  • Metabolic syndrome with hyperglycaemia: assists in reducing fasting and post‑prandial glucose concentrations.

How It Works

  • Metformin Hydrochloride reduces hepatic gluconeogenesis and increases peripheral insulin sensitivity, while Sitagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), leading to higher endogenous incretin levels that stimulate glucose‑dependent insulin release and suppress glucagon secretion. The combined actions provide additive reduction of plasma glucose concentrations.

Side Effects

Mifomet may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhoea.
  • Headache: mild to moderate intensity.
  • Mild hypoglycaemia: especially when combined with insulin or sulfonylureas.
  • Metallic taste: transient oral sensation.

Serious or Rare Side Effects

  • Lactic acidosis: a rare but life‑threatening metabolic complication.
  • Severe hypoglycaemia: marked low blood glucose requiring medical intervention.
  • Pancreatitis: acute inflammation of the pancreas presenting with abdominal pain.
  • Allergic reactions: rash, pruritus, or angio‑edema.
  • Hepatic or renal dysfunction: worsening of pre‑existing organ impairment.

Precautions & Warnings

When prescribing Mifomet, clinicians should consider several safety factors to minimise risk.

  • Renal function: assess creatinine clearance; avoid in severe renal impairment.
  • Hepatic disease: use with caution in patients with liver dysfunction.
  • Lactic acidosis risk: discontinue if signs of metabolic acidosis appear.
  • Concomitant insulin or sulfonylureas: monitor blood glucose closely to prevent hypoglycaemia.
  • Alcohol consumption: advise patients to limit intake as it may increase lactic acidosis risk.
  • Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Avoid Interactions

Mifomet can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

  • Iodinated contrast agents: may precipitate acute renal failure, increasing risk of metformin‑associated lactic acidosis.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise sitagliptin plasma levels, heightening hypoglycaemia risk.

Moderate Interactions (Monitor Closely)

  • Sulfonylureas or insulin: enhanced glucose‑lowering effect may cause hypoglycaemia.
  • Cimetidine: may modestly increase sitagliptin concentrations.
  • Diuretics (thiazides): can affect renal clearance of metformin, requiring dose adjustment.

Frequently Asked Questions

Mifomet is prescribed for adults with type 2 diabetes mellitus to improve blood glucose control. It combines metformin, which lowers hepatic glucose output, with sitagliptin, which enhances insulin secretion in response to meals, providing complementary mechanisms to achieve target glycaemic levels.

Metformin Hydrochloride primarily reduces the liver’s production of glucose and increases the sensitivity of muscle cells to insulin, allowing more efficient uptake of glucose from the bloodstream. This dual action helps lower fasting and post‑prandial blood sugar concentrations.

The specific dose of Mifomet is determined by the prescribing clinician based on the patient’s individual clinical profile, renal function, and response to therapy. Healthcare professionals adjust the dosage to achieve optimal glycaemic control while minimizing adverse effects.

Safety of Mifomet in pregnancy or lactation has not been fully established. Metformin is sometimes used off‑label in pregnancy under specialist supervision, while sitagliptin lacks sufficient data. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Mifomet combines two distinct mechanisms—biguanide action of metformin and DPP‑4 inhibition of sitagliptin—offering broader glucose control than either agent alone. Compared with sulfonylureas, it carries a lower intrinsic risk of hypoglycaemia, and unlike insulin, it is administered orally without injection.

Mifomet should be stored at ambient temperature, below 25 °C, in its original container to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Mifomet is taken orally, usually with meals to reduce gastrointestinal discomfort. The tablet should be swallowed whole with a glass of water and not crushed or chewed, unless otherwise directed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal metabolic condition, and severe hypoglycaemia, especially when used with insulin or sulfonylureas. Patients should be educated to recognize early symptoms and seek immediate medical attention if they occur.

Mifomet is contraindicated in patients with severe renal impairment (eGFR < 30 mL/min/1.73 m²), known hypersensitivity to metformin or sitagliptin, and those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease or acute heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Metformin Hydrochloride, Sitagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT